Active Ingredient(s):Ziv aflibercept FDA Approved: * August 3, 2012 Pharm Company: *SANOFI AVENTIS US Category:Cancer
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union.
It is an inhibitor of vascular endothelial growth factor (VEGF).
1 Medical uses
3 Adverse effects
5 Mechanism of action
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion